Rochester, NY – August 8, 2011. Dr. Maurice Zauderer, Vaccinex’s President and CEO, provided commentary in a recent BioCentury article about the importance of novel agents to promote remyelination in neurodegenerative diseases including multiple sclerosis. VX15 is Vaccinex’s lead drug candidate currently in Phase I testing for solid tumors. A second Phase I trial of VX15 in multiple sclerosis is planned to begin in 2012. Functional studies suggest that VX15 can promote remyelination of damaged neurons while also inhibiting the inflammation that triggers neurodegenerative disease. Such a dual mechanism of action could prove beneficial to patients at multiple stages of disease.